Nicox: research agreement with Glaukos Corporation

(CercleFinance.com) - Nicox announces that it has entered into an exclusive research agreement including a license option with Glaukos Corporation for NCX 1728, Nicox's nitric oxide (NO)-donating phosphodiesterase-5 (PDE-5) inhibitor.


Glaukos is a US-based ophthalmic pharmaceutical and medical device company specializing in innovative therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

The option will enable Glaukos to enter into exclusive worldwide licensing agreements on pre-agreed terms, including upfront and milestone payments as well as royalties.

Glaukos will fund and conduct preclinical research on NCX 1728, evaluating it in glaucoma (including neuroprotection) and other retinal diseases.

Glaukos is therefore an ideal partner to accelerate the research and development of this unique compound and exploit its therapeutic potential. We look forward to working with Glaukos to evaluate the use of this new molecule in a variety of indications. said Doug Hubatsch, Chief Scientific Officer of Nicox.

Copyright (c) 2024 CercleFinance.com. All rights reserved.